VitriVax Raises $87M Series C for a Lyme Disease Vaccine
VitriVax, a Boulder, Colorado developer of a Lyme disease vaccine, raised an $87M Series C, CEO Romulo Colindres told Axios Pro in an exclusive. Axios lists F-Prime, NEA, RA Capital, Sanofi Ventures and Eli Lilly among the backers; no lead investor or valuation was disclosed, and no company press release was available at publication time. Axios Pro: https://www.axios.com/pro/biotech-deals/2026/11/18/vitrivax-87m-lyme-disease-vaccine
Why the market is open: there is no approved Lyme disease vaccine for people today. Pfizer and Moderna both have clinical-stage candidates, so VitriVax is a small company walking into a race with two of the biggest vaccine makers in the world.
Having Sanofi Ventures and Lilly on the cap table is the tell. Two large pharma groups putting money into a would-be competitor of Pfizer usually means they want an option on the asset if it works. Details on trial stage and use of funds were behind the Axios paywall, so treat this one as a headline until the company publishes more.
← Back to all articles
Why the market is open: there is no approved Lyme disease vaccine for people today. Pfizer and Moderna both have clinical-stage candidates, so VitriVax is a small company walking into a race with two of the biggest vaccine makers in the world.
Having Sanofi Ventures and Lilly on the cap table is the tell. Two large pharma groups putting money into a would-be competitor of Pfizer usually means they want an option on the asset if it works. Details on trial stage and use of funds were behind the Axios paywall, so treat this one as a headline until the company publishes more.
Comments